Accolade entered into a definitive agreement to be acquired by Transcarent for $7.03 per share in cash, representing a total equity value of approximately $621 million. The company withdrew its previous financial guidance for the fiscal year and will not host its previously scheduled conference call.

Accolade reported revenue of $106.4 million and a net loss of $23.9 million for the fiscal second quarter ended August 31, 2024. The company is focused on delivering Adjusted EBITDA profitability and positive cash flow for the full fiscal year 2025.

Accolade announced financial results for the fiscal first quarter ended May 31, 2024, with a focus on profitable growth and positive Adjusted EBITDA.

Accolade reported revenue of $124.8 million and a net loss of $7.5 million for the fiscal fourth quarter ended February 29, 2024. Adjusted EBITDA was $18.5 million. The company is focused on delivering full year profitability on an Adjusted EBITDA basis.

Accolade announced financial results for the fiscal third quarter ended November 30, 2023. The company exceeded both top and bottom line guidance and is raising its guidance for fiscal year 2024. They are affirming their expectation for approximately 20% revenue growth and Adjusted EBITDA between 2% - 4% in fiscal year 2025.

Accolade announced strong financial results for the fiscal second quarter ended August 31, 2023, with revenue of $96.9 million and a net loss of $32.8 million. The company's customer base now exceeds 1,000, and cost reduction measures are expected to be fully realized in the second half of the year.

Accolade's Q1 2024 financial results demonstrated consistent strength, reinforcing the company's belief in an advocacy-led care delivery strategy. The company exceeded both top and bottom line guidance, driven by a growing customer base and sales momentum. Growth in virtual primary care is especially exciting. The 'One Accolade' initiative is creating a more streamlined organization, benefiting overall costs, decision making and strategic planning.

Accolade reported a 6% increase in revenue for the fiscal fourth quarter 2023, reaching $99.0 million, compared to $93.8 million in the fiscal fourth quarter 2022. The company's net loss was $(30.4) million. Accolade delivered against its financial objectives, highlighted by more than 30% growth in new ARR bookings and similarly strong growth driven by their virtual primary care offering.

Accolade reported a 9% increase in revenue for the fiscal third quarter 2023, reaching $90.9 million compared to $83.5 million in the fiscal third quarter 2022. The company's net loss was $(39.9) million, compared to a net income of $22.5 million last year.

Accolade reported a 20% increase in revenue for the fiscal second quarter 2023, reaching $87.6 million compared to $73.3 million in the fiscal second quarter 2022. The company experienced strong win rates across various industries and offerings, highlighting the increasing importance of offering a full range of solutions to both enterprise customers and health plan partners.

Accolade reported a strong first quarter with revenue of $85.5 million, a 44% increase year-over-year. The company is raising the midpoint of its revenue guidance for fiscal year 2023 and reaffirming its commitment to consistently improve its Adjusted EBITDA loss, with an expectation for positive cash flow and Adjusted EBITDA in fiscal year 2025.

Accolade reported a strong Q4 with revenue reaching $93.8 million, a 58% increase year-over-year. The company's net loss was $(34.6) million. Despite a strong pipeline, Accolade is moderating top-line growth objectives due to a large customer ending their service relationship and broader macro-environment concerns.

Accolade reported a strong fiscal third quarter with revenue of $83.5 million, a 117% increase year-over-year, driven by earlier than expected achievement of performance-based revenue. The company also introduced preliminary guidance for fiscal year 2023, expecting 25% revenue growth.

Accolade announced financial results for the fiscal second quarter ended August 31, 2021, with revenue of $73.3 million, a 99% increase compared to the previous year. The company introduced the Personalized Healthcare category and launched Accolade One and Accolade Care.

Accolade reported a strong first quarter with revenue of $59.5 million, a 66% increase compared to the first quarter of fiscal year 2021. The company raised its full year guidance for fiscal year 2022 to $300 million - $305 million.

Accolade reported a 33% increase in fiscal fourth quarter revenue, reaching $59.2 million compared to $44.4 million in the same period last year. The company's fiscal year 2021 revenue grew by 29% to $170.4 million. Accolade is expanding its market presence through the acquisition of 2nd.MD and the proposed acquisition of PlushCare.

Accolade reported a 30% increase in revenue for the fiscal third quarter 2021, driven by new customer additions across market segments and offerings. The company raised its revenue outlook for fiscal year 2021 to a range of $162 million to $165 million. However, the company reported a net loss of $16.6 million.

Accolade reported a 24% increase in revenue for the fiscal second quarter 2021, driven by strength in new customer additions across segments and offerings. The company's net loss was $(15.4) million compared to $(15.0) million for the same period last year.

Accolade reported a 25% increase in revenue for the fiscal first quarter 2021, reaching $35.9 million, driven by new customer acquisitions across segments and offerings. The company launched a pilot program with the Defense Health Agency, marking its entry into the federal government sector.